SANARA MEDTECH INC (SMTI)
Health Care · Surgical wound care and bone fusion implants · NASDAQ
Sanara MedTech develops surgical wound care and bone fusion implant solutions designed to improve clinical outcomes and reduce healthcare costs in the operating room.
What SANARA MEDTECH INC does
Sanara MedTech is a medical technology company developing and commercializing surgical solutions focused on soft tissue repair and bone fusion products. The company's primary offerings include CellerateRX Surgical Powder (a hydrolyzed collagen for surgical wound management), BIASURGE Advanced Surgical Solution (a sterile surgical irrigation solution), BiFORM Bioactive Moldable Matrix (an osteoconductive implant for bone fusion), and ALLOCYTE Plus Advanced Viable Bone Matrix. These products are designed to improve clinical outcomes and reduce healthcare expenditures in surgical settings.
Themes: Surgical wound care, Bone fusion implants, Soft tissue repair, Orthopedic and surgical solutions
Fundamentals
- Price$34.45 as of 2026-08-21 close
- Market cap$317M as of 2026-08-21
- 1-year return+12.9% 2025-08-21 close $30.52 → 2026-08-21 close $34.45
- P/En/a negative earnings
- Net margin-38.6% as of 2026-08-24
- Gross margin+93.1% as of 2026-08-24
- ROE-246.4% as of 2026-08-24
- Debt / equity6.58 as of 2026-08-24
- Revenue growth (YoY)-10.8% as of 2026-08-24
- Revenue CAGR (3y)+31.0% SEC XBRL
- Beta1.19 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How SMTI compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SANARA MEDTECH INC looks technically
SANARA MEDTECH INC (SMTI) is trading 51.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 24 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 57, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 80, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It just made a new 20-day high, its first since 2025-09-18, pushing above its recent trading range. It is 4.2% below its 52-week high (its highest price of the past year).
Trend
9
| Distance from the 200-day | it is trading 51.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +51.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $27.48 | $27.48 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $22.77 | $22.77 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 26. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 24 trading days ago — a "golden cross", a bullish long-term signal | 24 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 51.3% above | +51.3% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 57, with buyers in control | 56.9 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 80, in overbought territory (above 70) | 80.0 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($33.68 to $34.45) — its "stochastic" reading is 100 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 100.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $35.95 | $35.95 |
|---|---|---|
| From the 52-week high | it is 4.2% below its 52-week high (its highest price of the past year) | -4.2% |
| Above the 52-week low | it is 114.6% above its 52-week low (its lowest price of the past year) | +114.6% |
| Below the 52-week high | it is 4.2% below its highest point of the past year | 4.2% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2025-09-18, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2025-09-18, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $7800.00 (set on 1997-08-19) | $7800.00 |
| Given back of the 52-week move | over the past year its closes ranged ($16.34 to $35.75), and it has recovered almost all of its fall from last year’s high — 93% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $28.34 to $28.96. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 93.3% |
| From the all-time high | it is 99.6% below its all-time high | -99.6% |
| Nearest price level | it is sitting right on a support level at $34.43 — a price it turned at four times since 2024-12-05, most recently on 2026-08-12. Since 2024-08-21 it has 15 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.1% |
| All-time low | its lowest closing price on record is $2.00 (set on 2015-09-15) | $2.00 |
| Above the all-time low | it is 1622.5% above its all-time low | +1,623% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 75% of it) | 75th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6898 between its high and its low — about 2.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6898 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $28.24 and $38.10 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $28.24 – $33.17 – $38.10 |
| Typical daily range (% of price) | its price moves about 2.0% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.0% |
| Stretch from the 200-day average | it is trading 16.9 daily ranges above its 200-day average price (51.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 16.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.18× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 10.6% above the previous close 16 sessions ago and has not traded back through the level it left behind at 30.25 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +10.6% |
| Gap filled | a 2.6% gap down opened on 2026-07-09 has been "filled" 30 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 30 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 32.8 percentage points (the stock gained 35.1% while the market gained 2.3%) | +32.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 42.6 percentage points (the stock gained 45.7% while the market gained 3.1%) | +42.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 57.4 percentage points (the stock gained 68.5% while the market gained 11.1%) | +57.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 7.6 percentage points (the stock gained 12.9% while the market gained 20.5%) | -7.6% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 44% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.7% of the share price. | +44.5% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 24% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $27.84 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +23.7% |
|---|
Price levels it has turned at before
SMTI last closed at $34.45 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $34.43 | Support | 0.1% below the last close | turned there four times · 2024-12-05 to 2026-08-12 |
| $35.14 | Resistance | 2.0% above the last close | turned there five times · 2024-10-22 to 2025-10-08 |
| $33.44 | Support | 2.9% below the last close | turned there three times · 2025-02-13 to 2026-08-10 |
| $36.11 | Resistance | 4.8% above the last close | turned there four times · 2024-08-30 to 2025-09-08 |
| $32.51 | Support | 5.7% below the last close | turned there twice · 2024-11-12 to 2025-09-03 |
| $38.84 | Resistance | 12.7% above the last close | turned there three times · 2024-11-13 to 2025-01-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $26.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $28.70 and $31.70 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · MACD just crossed bearish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$35.00 range $35.00 – $35.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SMTI
- Consensus EPS estimate-$0.07 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Revenue declining with -10.8% YoY growth and negative net margins of -38.64%, indicating ongoing profitability challenges","Significant debt burden of $46.2 million in long-term debt against a relatively small equity base of $7.0 million, creating substantial financial leverage risk","Dependence on market acceptance and clinical adoption of proprietary surgical products in a competitive surgical solutions market"]
What changed in the latest 10-Q
AI-assisted comparison of SMTI's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K for year ended December 31, 2025 (newer filing, filed 2026-05-12)
- Addition of TEXAGEN Amniotic Membrane Allograft in soft tissue repair products description
- Addition of ACTIGEN Verified Inductive Bone Matrix in bone fusion products description
- Updated pipeline description: 'advancing a strong pipeline of next-generation products that supports and extends our surgical strategy of "Prepare, Promote and Protect."' (newer filing)
- Updated section header from 'Summary of Our Product, Service and Technology Offerings and Development Programs' to 'Summary of Our Key Products and Development Programs' (newer filing)
- Removed:
- Reference to Form 10-K for year ended December 31, 2024 (older filing, filed 2025-11-12)
- Reference to 'wound and skin services' in forward-looking statements topic examples
- Phrase 'services and technologies' in OVERVIEW - changed to focus on products only
- Phrase 'and patients' after 'treatments' in OVERVIEW goal statement
- Reference to 'physicians, clinics, and post-acute care settings' in customer description - newer version states 'surgeons at hospitals and surgical centers'
- Reference to 'advanced wound care markets' - newer version removes this market reference
- Phrase about 'constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost'
- Product name variation: 'CellerateRX Surgical Activated Collagen' changed to 'CellerateRX Surgical' (without 'Activated Collagen')
- Reference to 'CellerateRX Surgical powder' specification - newer version generalizes to 'CellerateRX Surgical'
- Extended product description phrase 'The majority of CellerateRX Surgical products are used for a variety of surgical wounds'
- Reference to 'Surgeons use CellerateRX Surgical to complement the body's normal healing process' in final paragraph
- Reference to reimbursement policies in risk factors bullet
- Reworded:
- Forward-looking statement risk factors bullet changed from 'the effects of current and future laws, rules, regulations and reimbursement policies relating to the labeling, marketing and sale of our products, and our planned launch of value-based wound, skin and other services' to 'the effects of current and future laws, rules and regulations relating to the labeling, marketing and sale of our products'
- OVERVIEW opening statement changed from 'Our products, services and technologies are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for patients' to 'Our products are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for healthcare systems'
- OVERVIEW description changed from 'expand our offerings for patients requiring treatments' to 'expand our offerings for patients requiring surgical treatments'
- Market description changed from 'We market and distribute surgical products to surgeons at hospitals and surgical centers' (newer) vs 'physicians, hospitals, clinics, and post-acute care settings' (older)
- Market focus changed from 'U.S. surgical tissue repair and advanced wound care markets' to 'U.S. surgical tissue repair market'
- Product pipeline description revised from 'extensive pipeline of innovative products under development' to 'strong pipeline of next-generation products'
- CellerateRX Surgical description in context: newer version includes TEXAGEN and ACTIGEN products not mentioned in older version
- Notes:
- The two filings appear to have different cutoff points in the MD&A section, with the newer filing's text being truncated mid-sentence at the end; comparison is limited to the available complete text
- Strategic focus shift from broader wound/skin services and post-acute care markets to surgical-focused offerings is evident but reflected in multiple cumulative wording changes rather than single discrete changes
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SMTI — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SMTI as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 388,141
- Reported value $6,668,262
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SMTI had 216,090 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SMTI had 2.35% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1 days to cover at the same settlement.
- Reported short interest (shares) 216,090
- Short interest (% of shares outstanding) 2.35%
- Prior settlement (shares) 377,539
- Reported change -42.76%
- Days to cover (reported) 1
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Zimmer Biomet (ZBH)
- Stryker Corporation (SYK)
- DePuy Synthes (J&J subsidiary)
- Arthrex
- Smith & Nephew
- Integra LifeSciences (IART)
- Organogenesis Holdings (ORGO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SMTI vs…
Frequently asked questions
What does SANARA MEDTECH INC (SMTI) do?
Sanara MedTech is a medical technology company developing and commercializing surgical solutions focused on soft tissue repair and bone fusion products. The company's primary offerings include CellerateRX Surgical Powder (a hydrolyzed collagen for surgical wound management), BIASURGE Advanced Surgical Solution (a sterile surgical irrigation solution), BiFORM Bioactive Moldable Matrix (an osteoconductive implant for bone fusion), and ALLOCYTE Plus Advanced Viable Bone Matrix.
What sector is SANARA MEDTECH INC (SMTI) in?
SANARA MEDTECH INC (SMTI) is classified in the Health Care sector. Its industry is Surgical wound care and bone fusion implants. It trades on NASDAQ.
Who are SANARA MEDTECH INC's (SMTI) competitors?
Notable peers of SANARA MEDTECH INC (SMTI) include Zimmer Biomet, Stryker Corporation, DePuy Synthes (J&J subsidiary), Arthrex and Smith & Nephew. This peer set is informational only — not financial advice.
Is SANARA MEDTECH INC (SMTI) overbought or oversold right now?
SANARA MEDTECH INC (SMTI) is currently in overbought territory (its 14-day RSI is 80, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SMTI come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.